Comments
Granules India received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Venlafaxine Hydrochloride Extended-Release Capsules.
The approved drug is bioequivalent to the reference listed drug product (RLD), Effexor XR Extended-Release Capsules of Upjohn US 2 LLC.
Venlafaxine HCl extended-release capsules are indicated for the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD) and Panic Disorder (PD)
Granules now have a total of 56 ANDA approvals from USFDA (54 final approvals and two tentative approvals).
The current annual U.S. market for Venlafaxine ER Capsules is approximately $153 million, according to IQVIA/IMS Health, the company said in a release.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.